Search Result

Results for "

PPARα/PPARδ agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Adenosine Receptor (1) Endogenous Metabolite (1) Estrogen Receptor/ERR (1) Fatty Acid Synthase (FASN) (1) Free Fatty Acid Receptor (2) Isotope-Labeled Compounds (2) Ligands for Target Protein for PROTAC (1) PPAR (31) Reference Standards (6)
By Research Areas:	Cancer (3) Cardiovascular Disease (9) Endocrinology (1) Inflammation/Immunology (9) Metabolic Disease (28)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13861

GW7647 20+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent *PPARα* agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-16995

Pirinixic acid Maximum Cited Publications 33 Publications Verification Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of *PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα* and PPARγ, and 5.0 μM, 60 μM, 35 μM for human *PPARα, PPARγ and PPARδ*, respectively.

HY-B0637

Bezafibrate 10+ Cited Publications BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-19522

Seladelpar 1 Publications Verification MBX-8025; RWJ-800025	PPAR	Metabolic Disease
Seladelpar (MBX-8025) is an orally active, potent and specific *PPARδ* agonist with an EC₅₀ of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .

HY-13928

GW0742 15+ Cited Publications GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and *PPARδ* agonist, with an IC₅₀ of 1 nM for human *PPARδ* in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human *PPARδ, PPARα, and PPAR*γ, respectively.

HY-106266

Chiglitazar 1 Publications Verification Carfloglitazar	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

HY-112813

TUG-1375 4 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-14817

Indeglitazar PPM 204	PPAR	Metabolic Disease
Indeglitazar (PPM 204) is an orally available *PPAR* pan-agonist for all three PPARα, PPARδ and PPARγ .

HY-U00425

PROTAC ERRα ligand 1	Ligands for Target Protein for PROTAC Estrogen Receptor/ERR	Metabolic Disease Cancer
PROTAC ERRα ligand 1 is a PROTAC target protein ligand. PROTAC ERRα ligand 1 is an orally active ERRα inverse agonist with IC₅₀ values of 0.6 μM for ERRα. PROTAC ERRα ligand 1 shows no significant activity against a panel of other nuclear receptors, including ERα ^c, ERRγ, ERβ, PPARα, PPARγ, PPARδ, and RXRα. PROTAC ERRα ligand 1 can provide enhanced insulin sensitivity in vivo. PROTAC ERRα ligand 1 can be used for metabolic diseases research, such as type 2 diabetes and obesity .

HY-106278

GW 590735 1 Publications Verification	PPAR	Metabolic Disease
GW 590735 is a potent and selective *PPARα* agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

HY-19522A

Seladelpar sodium 1 Publications Verification MBX-8025 sodium; RWJ-800025 sodium	PPAR	Metabolic Disease Inflammation/Immunology
Seladelpar (MBX-8025) sodium salt is an orally active, potent and specific *PPARδ* agonist with an EC₅₀ of 2 nM. Seladelpar sodium salt shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar sodium salt hydrochloride can be used for the study of primary biliary cholangitis .

HY-B0637S

Bezafibrate-d6	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent **PPARα/PPARδ** dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-Y1624

1,1'-(Azodicarbonyl)-dipiperidine ADDP; SR 4077	Free Fatty Acid Receptor PPAR	Metabolic Disease
1,1'-(Azodicarbonyl)-dipiperidine (ADDP) can be used in the condensation reaction of alcohols with acidic compounds. 1,1'-(Azodicarbonyl)-dipiperidine can also be used in the synthesis of GPR120 agonists with antidiabetic activity, as well as the synthesis of triple agonists for *PPARα, PPARγ, and PPARδ*. 1,1'-(Azodicarbonyl)-dipiperidine can be used in metabolic disease research .

HY-13928R

GW0742 (Standard) GW610742 (Standard)	PPAR Reference Standards	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 (Standard) is the analytical standard of GW0742. This product is intended for research and analytical applications. GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

HY-106266B

Chiglitazar sodium 1 Publications Verification Carfloglitazar sodium	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

HY-19425

NS-220	PPAR	Metabolic Disease
NS-220 is an orally active *PPARα* agonist with high subtype selectivity, with EC₅₀ values of 1.9×10 ^-8 M, 9.6×10 ^-6 M and >10 ^-4 M for PPARα, PPAR γ and PPARδ, respectively. NS-220 is used in the research for hyperlipidemia or metabolic disorders in type-2 diabetes .

HY-19522B

Seladelpar (lysine) 1 Publications Verification MBX-8025 (lysine); RWJ-800025 (lysine)	PPAR	Metabolic Disease
Seladelpar (MBX-8025) lysine is an orally active, potent and specific *PPARδ* agonist with an EC₅₀ of 2 nM. Seladelpar lysine shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar lysine can be used for the study of primary biliary cholangitis .

HY-19522R

Seladelpar (Standard) MBX-8025 (Standard); RWJ-800025 (Standard)	PPAR Reference Standards	Metabolic Disease
Seladelpar (Standard) is the analytical standard of Seladelpar. This product is intended for research and analytical applications. Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis .

HY-178958

PPAR agonist 7	PPAR Adenosine Receptor Fatty Acid Synthase (FASN) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology
PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, *PPARα* (EC₅₀ = 1.51 μM), *PPARδ* (EC₅₀ = 1.11 μM), and PPARγ (EC₅₀ = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/ Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes .

HY-120886

GW 2433	PPAR	Metabolic Disease
GW 2433 is a dual *PPARα* and *PPARδ* agonist. GW 2433 has the potential for the study of type II diabetes and dyslipidemia .

HY-B0637S1

Bezafibrate-d4 BM15075-d₄	Isotope-Labeled Compounds PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637R

Bezafibrate (Standard) BM15075 (Standard)	Reference Standards PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-162123

PPARα/δ agonist 2	PPAR	Inflammation/Immunology
PPARα/δ agonist 2 (compound 14) is a potent *PPARα* and *PPARδ* agonist with EC₅₀s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/δ agonist 2 shows anti-inflammatory effects .

HY-B0637S2

Bezafibrate-13C6 BM15075-¹³C₆	Isotope-Labeled Compounds PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-13861R

GW7647 (Standard)	PPAR	Cardiovascular Disease
GW7647 (Standard) is the analytical standard of GW7647. This product is intended for research and analytical applications. GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-16995R

Pirinixic acid (Standard) Wy-14643 (Standard)	PPAR Reference Standards	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Standard) is the analytical standard of Pirinixic acid. This product is intended for research and analytical applications. Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-121798

TZD18	PPAR	Metabolic Disease
TZD18 is a potent and orally active *PPARα* and PPARγ dual agonist with IC₅₀ values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes .

HY-163443

PPAR agonist 4	PPAR	Others
PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC₅₀s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy .

HY-168485

PPARα/δ agonist 3	PPAR	Metabolic Disease
PPARα/δ agonist 3 (Compound 8) is the orally active agonist for *PPAR, that activates PPARα, PPARδ* and PPARγ with EC₅₀s of 5.6, 3.4 and 1278 nM, respectively. PPARα/δ agonist 3 exhibits anticholestatic activity in mouse ANIT- or CDCA (HY-76847)-induced cholestatic liver disease models .

HY-179015

HSD17B13/PPAR modulator-1	17β-HSD PPAR	Metabolic Disease Inflammation/Immunology
HSD17B13/PPAR modulator-1 (Compound 17) is a *HSD17B13/PPAR* multitarget modulator. HSD17B13/PPAR modulator-1 is an inhibitor of HSD17B13, with its IC₅₀ value being 0.91 μM. HSD17B13/PPAR modulator-1 is a *PPAR* agonist, with the EC₅₀ values for PPARα, PPARδ, and PPARγ being 1.55, 0.12, and 0.01 μM respectively. HSD17B13/PPAR modulator-1 can significantly improve liver function, regulate lipid metabolism, alleviate fibrosis, and exert antioxidant and anti-inflammatory effects in the model of metabolic dysfunction-related steatohepatitis (MASH). HSD17B13/PPAR modulator-1 can be used for the study of MASH .

HY-106278R

GW 590735 (Standard)	Reference Standards PPAR	Metabolic Disease
GW 590735 (Standard) is the analytical standard of GW 590735 (HY-106278). This product is intended for research and analytical applications. GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

HY-106266R

Chiglitazar (Standard) Carfloglitazar (Standard)	Reference Standards PPAR	Metabolic Disease
Chiglitazar (Standard) is the analytical standard of Chiglitazar (HY-106266). This product is intended for research and analytical applications. Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

Cat. No.	Product Name	Chemical Structure

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S2

Bezafibrate-13C6
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: